GARDASIL9
Biological
Merck Sharp & Dohme Corporation
Total Payments
$3.3M
Transactions
6,255
Doctors
4,328
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $567,903 | 1,097 | 899 |
| 2018 | $700,633 | 1,900 | 1,534 |
| 2017 | $2.1M | 3,258 | 2,522 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.0M | 388 | 90.2% |
| Consulting Fee | $215,085 | 64 | 6.5% |
| Food and Beverage | $80,296 | 5,777 | 2.4% |
| Travel and Lodging | $25,221 | 20 | 0.8% |
| Space rental or facility fees (teaching hospital only) | $2,850 | 4 | 0.1% |
| Education | $1,589 | 2 | 0.0% |
Payments by Type
Research
$3.0M
388 transactions
General
$325,041
5,867 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Post licensure Observational Safety Study of Gardasil 9 | Merck Sharp & Dohme Corporation | $962,441 | 0 |
| A Phase III Clinical Trial to Study the Immunogenicity, Tolerability, and Manufacturing Consistency of V503 A Multivalent Human Papillomavirus HPV L1 Virus-Like Particle VLP Vaccine in Preadolescents and Adolescents 9 to 15 year olds with a Comparison to Young Women 16 to 26 year olds | Merck Sharp & Dohme Corporation | $574,796 | 0 |
| A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of a 2-dose regimen of V503, a Multivalent Human Papillomavirus HPV L1 Virus-Like Particle VLP Vaccine, administered in Preadolescents and Adolescents 9 to 14 year olds with a Comparison to Young Women 16 to 26 year olds | Merck Sharp & Dohme Corporation | $492,113 | 1 |
| Human papillomavirus antibody response after GARDASIL 9 vaccination in patients after allogeneic stem cell transplantation | Merck Sharp & Dohme Corporation | $256,334 | 0 |
| V503-049 A Phase 3, International, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Virus-like Particle Vaccine, in the prevention of oral persistent infection with HPV Types 16, 18, 31, 33, 45, 52, or 58 in adult males, 20 to 45 years of age | Merck Sharp & Dohme Corporation | $165,648 | 0 |
| Post Licensure Observational Safety Study f Gardasil 9 | Merck Sharp & Dohme Corporation | $146,070 | 0 |
| A randomized, placebo-controlled trial of HPV vaccination to reduce cervical high-grade squamous intraepithelial lesions among HIV-infected women participating in an HPV test-and-treat program COVENANT | Merck Sharp & Dohme Corporation | $72,007 | 0 |
| Post-Licensure Observational Safety Study of Gardasil 9 | Merck Sharp & Dohme Corporation | $59,921 | 0 |
| Immunogenicity of Nonavalent HPV Vaccine Administered Prior To Living Donor Renal Transplantation in Adult Women A Prospective, Single-Arm, Multi-Center Clinical Trial | Merck Sharp & Dohme Corporation | $55,850 | 0 |
| Human Papilloma Virus HPV Path Panel | Merck Sharp & Dohme Corporation | $55,778 | 0 |
| HPV Vaccine to Interrupt Progression of Vulvar and Anal Neoplasia VIVA Trial A Randomized, Double-Blind, Placebo-Controlled Trial | Merck Sharp & Dohme Corporation | $42,588 | 0 |
| Immunization with the Gardasil-9 HPV Vaccine in the Immediate Postpartum Period as a Targeted Intervention to Increase Vaccine Uptake A Pilot Implementation Study | Merck Sharp & Dohme Corporation | $42,027 | 0 |
| A Randomized, International, Double-Blinded With In-House Blinding, Controlled With GARDASILTM, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavirus HPV L1 Virus-Like Particle VLP Vaccine Administered to 16- to 26-Year-Old Women | Merck Sharp & Dohme Corporation | $29,853 | 0 |
| A prospective single-subject experimental design study to evaluate the efficacy of Gardasil-9 in elevating antibody titers to human papilloma virus HPV in surgeons with occupational high-risk exposure to HPV. | Merck Sharp & Dohme Corporation | $20,813 | 0 |
| Postpartum HPV Vaccination Acceptability, Uptake and Immunogenicity | Merck Sharp & Dohme Corporation | $10,725 | 0 |
| Immunogenicity of Nonavalent HPV Vaccine Administered Prior To Living Donor Renal Transplantation in Adult Women# A Prospective, Single-Arm, Multi-Center Clinical Trial | Merck Sharp & Dohme Corporation | $8,047 | 0 |
| An open label, phase 2 study to assess the immunogenicity of the ninevalent HPV recombinant vaccine in patients with idiopathic CD4 T cells lymphocytopenia ICL | Merck Sharp & Dohme Corporation | $4,082 | 0 |
| A Phase III, Randomized, International, Placebo-Controlled, Double-Blind Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus HPV L1 Virus-Like Particle VLP Vaccine, Given to Females 12-26 Years of Age Who Have Previously Received GARDASILTM | Merck Sharp & Dohme Corporation | $754.60 | 0 |
Top Doctors Receiving Payments for GARDASIL9 — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Margaret Wren | Pediatrics | Seaford, NY | $83.28 | 5 |
| , MD | Pediatrics | Millburn, NJ | $82.77 | 6 |
| , M.D | Pediatrics | New York, NY | $81.80 | 5 |
| , M.D | Adolescent Medicine | East Longmeadow, MA | $81.34 | 6 |
| , M.D | Pediatrics | Glen Cove, NY | $80.85 | 5 |
| , M.D | Pediatrics | Glen Cove, NY | $80.85 | 5 |
| , MD | Pediatrics | Millburn, NJ | $80.41 | 6 |
| , MD | Adolescent Medicine | Dayton, OH | $78.02 | 6 |
| , M.D | Sports Medicine | Hamilton, NJ | $77.57 | 6 |
| , MD | Pediatrics | Hamilton, NJ | $76.29 | 6 |
| , DO | Pediatrics | East Windsor, NJ | $73.77 | 6 |
| , MD | Pediatrics | Scarsdale, NY | $73.62 | 5 |
| , MD | Pediatrics | Scarsdale, NY | $73.62 | 5 |
| , M.D | Adolescent Medicine | East Windsor, NJ | $72.19 | 6 |
| , MD | Pediatrics | Jericho, NY | $71.66 | 4 |
| , DO | Pediatrics | Jericho, NY | $71.66 | 4 |
| , D.O., P.C | Pediatrics | Grand Junction, CO | $71.12 | 5 |
| , MD | Health Maintenance Organization | Trenton, NJ | $70.69 | 6 |
| , M.D | Pediatrics | Orlando, FL | $69.62 | 6 |
| Jasmine Ramos | Pediatrics | Palm Desert, CA | $68.60 | 5 |
| , M. D | Pediatric Nephrology | Santurce, PR | $67.71 | 1 |
| , MD | Pediatrics | Bayamon, PR | $67.71 | 1 |
| , MD | Pediatrics | Columbia, SC | $67.71 | 1 |
| , M.D | Pediatrics | Toa Baja, PR | $67.71 | 1 |
| , MD | Pediatrics | Warrington, PA | $67.61 | 5 |
Ad
Manufacturing Companies
Product Information
- Type Biological
- Total Payments $3.3M
- Total Doctors 4,328
- Transactions 6,255
About GARDASIL9
GARDASIL9 is a biological associated with $3.3M in payments to 4,328 healthcare providers, recorded across 6,255 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2019. In 2019, $567,903 was paid across 1,097 transactions to 899 doctors.
The most common payment nature for GARDASIL9 is "Unspecified" ($3.0M, 90.2% of total).
GARDASIL9 is associated with 18 research studies, including "Post licensure Observational Safety Study of Gardasil 9" ($962,441).